4//SEC Filing
Dayno Jeffrey M. 4
Accession 0001415889-25-001931
CIK 0001802665other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:17 PM ET
Size
13.5 KB
Accession
0001415889-25-001931
Insider Transaction Report
Form 4
Dayno Jeffrey M.
DirectorPRESIDENT, CEO
Transactions
- Exercise/Conversion
Common Stock
2025-01-21$8.22/sh+19,293$158,588→ 19,293 total - Exercise/Conversion
Stock Option
2025-01-21−6,086→ 0 totalExercise: $8.22Exp: 2029-01-07→ Common Stock (6,086 underlying) - Sale
Common Stock
2025-01-21$40.13/sh−19,293$774,245→ 0 total - Exercise/Conversion
Stock Option
2025-01-21−9,737→ 2,435 totalExercise: $8.22Exp: 2030-03-04→ Common Stock (9,737 underlying) - Exercise/Conversion
Stock Option
2025-01-21−3,470→ 20,000 totalExercise: $8.22Exp: 2027-11-13→ Common Stock (3,470 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option vests in five equal annual installments beginning on November 1, 2018.
- [F4]The stock option vests in five equal annual installments beginning on January 1, 2020.
- [F5]The stock option vests in five equal annual installments beginning on March 1, 2021.
Documents
Issuer
Harmony Biosciences Holdings, Inc.
CIK 0001802665
Entity typeother
Related Parties
1- filerCIK 0001615993
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 4:17 PM ET
- Size
- 13.5 KB